38646
document
Ondansetron has similar clinical efficacy against both nausea and vomiting . Ondansetron is widely believed to prevent postoperative vomiting more effectively than nausea . We analysed data from 5161 patients undergoing general anaesthesia who were randomly stratified to receive a combination of six interventions , one of which was 4 mg ondansetron vs placebo . For the purpose of this study a 20 % difference in the relative risks for the two outcomes was considered clinically relevant . Nausea was reduced from 38 % ( 969/2585 ) in the control to 28 % ( 715/2576 ) in the ondansetron group , corresponding to a relative risk of 0.74 , or a relative risk reduction of 26 % . Vomiting was reduced from 17 % ( 441/2585 ) to 11 % ( 293/2576 ) , corresponding to a relative risk of 0.67 , or a relative risk reduction of 33 % . The relative risks of 0.67 and 0.74 were clinically similar and the difference between them did not reach statistical significance . We thus conclude that ondansetron prevents postoperative nausea and postoperative vomiting equally well .
38647
Intervention_Pharmacological
Ondansetron
38648
Intervention_Pharmacological
Ondansetron
38649
Intervention_Pharmacological
anaesthesia
38650
Intervention_Pharmacological
ondansetron
38651
Intervention_Control
placebo
38652
Intervention_Pharmacological
ondansetron
38653
Intervention_Pharmacological
ondansetron
38654
Outcome_Other
clinical efficacy
38655
Outcome_Adverse-effects
nausea
38656
Outcome_Adverse-effects
vomiting
38657
Outcome_Physical
vomiting
38658
Outcome_Physical
nausea
38659
Outcome_Physical
Nausea
38660
Outcome_Physical
Vomiting
38661
Outcome_Adverse-effects
postoperative nausea
38662
Outcome_Adverse-effects
postoperative vomiting